Doshi Dipal — SEC insider filings
SEC reporting owner CIK 1613084. 43 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 43 filings on record, filed 2021-11-01 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 49 legs across 27 filings — 86,992 shares, $1,387,752 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 7,506 shares @ $20.76 ($155,808) in Entrada Therapeutics, Inc., filed 2022-10-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | CEO, Director | 41 | — | 49 legs · 86,992 sh · $1,387,752 | 34 |
| Azenta, Inc. (AZTA) | Director | 2 | — | — | 2 |
Insider filings — Doshi Dipal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 8,724 @ $7.14 | EDGAR |
| 2026-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 139,400 @ $0 · Tax withholding (F): 9,869 @ $11.66 · Tax withholding (F): 19,181 @ $11.76 · Grant/award (A): 208,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 5,663 @ $27.85 | EDGAR |
| 2025-09-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 8,723 @ $5.43 | EDGAR |
| 2025-03-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 116,200 @ $0 · Tax withholding (F): 17,566 @ $11.68 · Grant/award (A): 173,400 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Azenta, Inc. (AZTA) | Grant/award (A): 4,040 @ $52.32 | EDGAR |
| 2024-09-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 2,328 @ $15.76 · Tax withholding (F): 752 @ $16.93 · Tax withholding (F): 72 @ $17.70 · Tax withholding (F): 4,744 @ $15.42 · Tax withholding (F): 826 @ $15.13 | EDGAR |
| 2024-07-16 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 300 @ $18 · Sale (S): 1,600 @ $17.81 | EDGAR |
| 2024-06-14 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $16.17 | EDGAR |
| 2024-05-20 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,800 @ $15 · Sale (S): 1,200 @ $15.11 | EDGAR |
| 2024-03-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 104,700 @ $0 · Tax withholding (F): 1,164 @ $12.42 · Tax withholding (F): 1,391 @ $13.37 · Tax withholding (F): 5,049 @ $12.28 · Grant/award (A): 158,500 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15 | EDGAR |
| 2024-01-18 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15.99 | EDGAR |
| 2023-12-22 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15 | EDGAR |
| 2023-11-13 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $16.23 | EDGAR |
| 2023-10-19 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15 | EDGAR |
| 2023-09-15 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15 | EDGAR |
| 2023-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 49,650 @ $0 · Tax withholding (F): 1,440 @ $14.46 · Grant/award (A): 75,250 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15.67 | EDGAR |
| 2023-05-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,000 @ $13.71 | EDGAR |
| 2023-04-19 | 4/A | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 49,650 @ $0 · Grant/award (A): 75,250 (derivative) @ $0 | EDGAR |
| 2023-04-19 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,092 @ $18.01 | EDGAR |
| 2023-03-29 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,800 @ $14.63 · Sale (S): 200 @ $15.51 | EDGAR |
| 2023-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 99,300 @ $0 · Tax withholding (F): 3,324 @ $11.60 · Grant/award (A): 150,500 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,000 @ $12 | EDGAR |
| 2023-01-30 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,000 @ $12.00 | EDGAR |
| 2023-01-10 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,410 @ $15.02 | EDGAR |
| 2022-12-29 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 600 @ $14.80 · Sale (S): 9,069 @ $15.04 · Sale (S): 4,521 @ $15.01 · Sale (S): 400 @ $15.01 | EDGAR |
| 2022-11-30 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,000 @ $13.91 | EDGAR |
| 2022-10-27 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,055 @ $20.01 · Sale (S): 7,506 @ $20.76 · Sale (S): 1,500 @ $21.50 · Sale (S): 2,000 @ $21.66 | EDGAR |
| 2022-10-24 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 811 @ $18.01 · Sale (S): 2,786 @ $18.28 · Sale (S): 1,101 @ $18.90 · Sale (S): 1,241 @ $19.65 | EDGAR |
| 2022-09-28 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,795 @ $15.22 · Sale (S): 288 @ $16.30 · Sale (S): 3,453 @ $15.04 · Sale (S): 966 @ $15.82 · Sale (S): 3,085 @ $15.23 | EDGAR |
| 2022-09-23 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,402 @ $15.12 · Sale (S): 1,023 @ $15.07 | EDGAR |
| 2022-09-19 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 200 @ $15.04 | EDGAR |
| 2022-09-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,100 @ $15.16 · Sale (S): 688 @ $15.07 | EDGAR |
| 2022-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 15,125 @ $0 | EDGAR |
| 2022-08-31 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,109 @ $12.56 · Sale (S): 505 @ $13.51 · Sale (S): 25 @ $14 · Sale (S): 190 @ $12 · Sale (S): 171 @ $12 | EDGAR |
| 2022-07-29 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,000 @ $12 | EDGAR |
| 2022-07-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 90,750 (derivative) @ $0 | EDGAR |
| 2022-06-29 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 4,000 @ $12 | EDGAR |
| 2022-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 30,250 @ $0 · Grant/award (A): 181,500 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Entrada Therapeutics, Inc. (TRDA) | Option exercise (M): 10,000 @ $1.74 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-11-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 184,821 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-27 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1613084 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs